Metabolic effects of darglitazone, an insulin sensitizer, in NIDDM subjects

Diabetologia
R L ChaikenH E Lebovitz

Abstract

Insulin resistance is a significant pathogenetic factor in the development of non-insulin-dependent diabetes mellitus (NIDDM). A new class of drugs, the thiazolidinediones, have been shown to lower blood glucose levels without stimulating insulin secretion. We report the metabolic effect of the thiazolidinedione, darglitazone, in obese NIDDM subjects. Nineteen subjects were enrolled in a double-blind placebo-controlled study in which 25 mg of darglitazone was given once a day for 14 days. Nine subjects received the active drug and ten subjects received placebo. Darglitazone-treated subjects showed; 1) a decrease in 24-h plasma glucose area under the curve from 292.8 +/- 31.2 to 235.2 +/- 21.6 mmol.h-1.l-1 p = 0.002; 2) a decrease in 24-h serum insulin area under the curve from 1027.2 +/- 254.4 to 765.6 +/- 170.4 microU.h-1.l-1 p = 0.045; 3) a decrease in 24-h non-esterified fatty acid area under the curve from 1900 +/- 236 to 947 +/- 63 g.h-1.l-1 p = 0.002; 4) a decrease in mean 24-h serum triglyceride by 25.9 +/- 6.2% as compared to -3.9 +/- 4.8% for the placebo-treated group, p = 0.012. Placebo-treated subjects showed no change in their metabolic parameters after treatment. Thus, darglitazone is effective in increasing insuli...Continue Reading

References

Oct 1, 1992·Diabetes Care·M A Banerji, H E Lebovitz
Nov 1, 1991·Diabetes Care·R L ChaikenH E Lebovitz
Mar 14, 1991·The New England Journal of Medicine·M F SaadB V Howard
Jun 1, 1990·Diabetes Care·R W Stout
Jun 1, 1989·Diabetes·M A Banerji, H E Lebovitz
Mar 1, 1988·Metabolism: Clinical and Experimental·J R ColcaA R Diani
Aug 6, 1987·The New England Journal of Medicine·E FerranniniS Bevilacqua
Sep 1, 1980·Analytical Biochemistry·S ShimizuT Murachi
Jun 1, 1980·The Journal of Clinical Investigation·O G KoltermanJ M Olefsky
Nov 3, 1994·The New England Journal of Medicine·J J NolanJ Olefsky
Mar 1, 1993·Diabetes·R L ChaikenH E Lebovitz

❮ Previous
Next ❯

Citations

Mar 1, 2005·European Journal of Internal Medicine·J R TimmerF Zijlstra
Aug 5, 2003·Metabolism: Clinical and Experimental·Marta SanturéHélène Bachelard
Jul 1, 1997·Trends in Endocrinology and Metabolism : TEM·R G Larkins
Jul 3, 2002·Drugs·Fabrice M A C MartensTon J Rabelink
Nov 19, 2003·American Journal of Veterinary Research·Margarethe Hoenig, Duncan C Ferguson
Jun 1, 2001·Journal of Endocrinological Investigation·R Perfetti, K Chamie
Nov 4, 2000·Expert Opinion on Investigational Drugs·E Murphy, J J Nolan
Jun 1, 1997·Expert Opinion on Investigational Drugs·A J Mackay, J R Petrie
Mar 1, 2005·Biochimie·Mitchell A Lazar
May 4, 2001·Diabetes·S YonemitsuK Nakao
Jul 2, 2003·Nature Medicine·Garry D TanFredrik Karpe
Mar 12, 1998·Nature·K BourtzisS L O'Neill
Jul 9, 2013·The Journal of Veterinary Medical Science·Min-Chuan LaiChi Yang
Jan 10, 2001·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·U SmithB Svalstedt
Aug 31, 2019·Nutrients·Amélie I S SobczakAlan J Stewart
Jun 11, 2003·European Journal of Clinical Investigation·L SvenssonL M Hultén
Feb 26, 2000·Journal of Medicinal Chemistry·T M WillsonB R Henke

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.